Claims
- 1. A diarylmethylidenefuran compound of formula (I): ##STR25## wherein: the rings A and B independently are:
- a phenyl radical,
- a naphthyl radical,
- a pyridyl radical,
- a furyl radical, or
- a thienyl radical;
- at least one of the substituents X.sub.1, X.sub.2, Y.sub.1 or Y.sub.2 is necessarily:
- an S(O).sub.n --R group, in which n is an integer equal to 0, 1 or 2 and R is a lower alkyl radical having 1 to 6 carbon atoms or a lower haloalkyl radical having 1 to 6 carbon atoms, or
- an SO.sub.2 NH.sub.2 group; and is located in the para position,
- the others independently being:
- a hydrogen atom,
- a halogen atom,
- a lower alkyl radical having 1 to 6 carbon atoms,
- a trifluoromethyl radical,
- a lower O-alkyl radical having 1 to 6 carbon atoms, and
- R.sub.1, R.sub.2, R.sub.3 and R.sub.4 independently are:
- a hydrogen atom,
- a halogen atom,
- a lower alkyl radical having 1 to 6 carbon atoms,
- a lower haloalkyl radical having 1 to 6 carbon atoms,
- an aromatic radical selected from the group consisting of phenyl and naphthyl, or
- R.sub.1 R.sub.2 or R.sub.3 R.sub.4 are an oxygen atom, or
- R.sub.1,R.sub.2 or R.sub.3,R.sub.4, together with the carbon atom to which they are attached, form a saturated hydrocarbon ring having from 3 to 7 carbon atoms.
- 2. A compound of formula (I) according to claim 1, wherein:
- the rings A and B independently are:
- a phenyl radical,
- a naphthyl radical,
- a pyridyl radical,
- a furyl radical, or
- a thienyl radical;
- at least one of the substituents X.sub.1, X.sub.2, Y.sub.1 or Y.sub.2 is necessarily SCH.sub.3, SO.sub.2 CH.sub.3 or SO.sub.2 NH.sub.2 group,
- the others independently being:
- a hydrogen atom,
- a halogen atom,
- a lower alkyl radical having 1 to 6 carbon atoms,
- a trifluoromethyl radical, or
- a lower O-alkyl radical having 1 to 6 carbon atoms;
- R.sub.1 R.sub.2 are an oxygen atom; and
- R.sub.3 R.sub.4 independently are a hydrogen atom or a lower alkyl radical having 1 to 6 carbons.
- 3. A compound according to claim 1, wherein the ring B is a phenyl radical.
- 4. A compound according to claim 1, wherein the ring A is a phenyl radical or a pyridyl radical.
- 5. A compound according to claim 1, wherein X.sub.1 is a 4-SO.sub.2 CH.sub.3 group or a 4-SO.sub.2 NH.sub.2 group, and X.sub.2 is a hydrogen atom.
- 6. A compound according to claim 1, wherein Y.sub.1 is a fluorine atom, a chlorine atom or a methyl radical, and Y.sub.2 is a hydrogen atom, a fluorine atom or a chlorine atom.
- 7. A compound according to claim 1, wherein R.sub.1 R.sub.2 are an oxygen atom and R.sub.3 and R.sub.4 are each a hydrogen atom.
- 8. A compound according to claim 1, which is selected from the following compounds: ##STR26##
- 9. A compound according to claim 1, and having the formula ##STR27##
- 10. A compound according to claim 1, and having the formula ##STR28##
- 11. A pharmaceutical composition, which comprises a pharmaceutically effective amount of a compound of formula (I) as defined in claim 1, incorporated in a pharmaceutically acceptable excipient, vehicle or carrier.
- 12. A pharmaceutical composition with anti-inflammatory and analgesic activity, which contains a pharmaceutically effective amount of a compound of formula (I) as defined in claim 1, incorporated in a pharmaceutically acceptable excipient, vehicle or carrier.
- 13. A pharmaceutical composition according to claim 11, which is in the form of gelatin capsules or tablets containing a dose of 1 mg to 1000 mg.
- 14. A pharmaceutical composition according to claim 11, which is in the form of injectable preparations containing a dose of 0.1 mg to 500 mg.
- 15. A method for treating inflammation in a mammal which comprises administering an anti-inflammatory effective amount of a compound of formula I as defined in claim 1 to said mammal.
- 16. A method for treating pain in a mammal which comprises administering an effective amount of a compound of formula I as defined in claim 1 to said mammal.
Priority Claims (2)
Number |
Date |
Country |
Kind |
96 04236 |
Apr 1996 |
FRX |
|
96 07922 |
Jun 1996 |
FRX |
|
Parent Case Info
This is a Continuation-in-Part application of originally filed application Ser. No. 08/714,742 filed on Sep. 16, 1996, now abandoned claiming priorities from French patent application No. 9604236 filed on Apr. 4, 1996 and from French patent application No. 9607922 filed on Jun. 26, 1996.
US Referenced Citations (7)
Foreign Referenced Citations (4)
Number |
Date |
Country |
WO9415932 |
Jul 1994 |
WOX |
WO9500501 |
Jan 1995 |
WOX |
WO9608482 |
Mar 1996 |
WOX |
WO9636623 |
Nov 1996 |
WOX |
Non-Patent Literature Citations (4)
Entry |
Gilbert, et al., J. Med. Chem., 1983, 26: 693-699. |
Katsumi, et al., Chem. Pharm. Bull., 1986, 34(1): 121-129. |
Katsumi, et al., Chem. Pharm. Bull., 1986, 34(4): 1619-1627. |
CA 122:265237 Imura et al., 1995. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
714742 |
Sep 1996 |
|